Jennison Associates LLC Crispr Therapeutics Ag Transaction History

Jennison Associates LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$53.19 - $79.24 $21.8 Million - $32.5 Million	-409,683 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$70.09 - $111.29 $511,446 - $812,083	-7,297 Reduced 1.75%	409,683 $31 Million
Q3 2021 Nov 09, 2021	BUY	$110.2 - $156.64 $15.6 Million - $22.2 Million	141,769 Added 51.51%	416,980 $46.7 Million
Q1 2021 May 11, 2021	SELL	$110.72 - $210.04 $230,629 - $437,513	-2,083 Reduced 0.75%	275,211 $33.5 Million
Q4 2020 Feb 05, 2021	SELL	$79.67 - $173.23 $223,633 - $486,256	-2,807 Reduced 1.0%	277,294 $42.5 Million
Q3 2020 Nov 04, 2020	BUY	$78.5 - $100.64 $71,670 - $91,884	913 Added 0.33%	280,101 $23.4 Million
Q2 2020 Aug 06, 2020	BUY	$38.5 - $76.05 $3.95 Million - $7.81 Million	102,689 Added 58.18%	279,188 $20.5 Million
Q1 2020 May 06, 2020	BUY	$33.68 - $62.53 $5.94 Million - $11 Million	176,499 New	176,499 $7.49 Million
Q4 2018 Feb 06, 2019	SELL	$22.73 - $42.34 $12.3 Million - $22.9 Million	-540,887 Closed	0 $0
Q3 2018 Nov 08, 2018	BUY	$44.35 - $65.71 $24 Million - $35.5 Million	540,887 New	540,887 $24 Million

494

64.3M

1.68M

1.95M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.88B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.